Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Measuring the Value of Therapies for Ultra-Rare Diseases
  The pricing of drugs is characterized by a tension between providing incentives to drug companies to invest in the development of… Continue Reading
Khondrion Reports Positive Preliminary Data on Mid-Stage Trial in MELAS and MIDD Syndromes
Rare Daily Staff Khondrion presented promising results from a mid-stage exploratory study of KH176, its experimental therapy to treat MELAS… Continue Reading
X4 Pharmaceuticals Raises $27 Million in Series B Financing
Rare Daily Staff X4 Pharmaceuticals said it completed a $27 million series B financing that will be used to fund a pivotal study of its lead… Continue Reading
That Other Thing in the Tax Bill Rare Disease Patients Should Worry About
The rare disease community has organized to fight a provision in the Republican tax bill that would repeal the Orphan Drug Tax Credit, an… Continue Reading
Failed COPD Drug Shows Promise as Treatment for Rare Bone Disease
Rare Daily Staff A drug Roche had unsuccessfully sought to develop as a treatment for chronic obstructive pulmonary disease has shown… Continue Reading
Shire Names Thomas Dittrich as CFO and Director
Rare Daily Staff Rare disease drug company Shire said it named Thomas Dittrich as its CFO and as a member of its board of directors. He… Continue Reading
Lessons from Pitching Venture Capitalists
Stories abound about plucky entrepreneurs financing their startups, but it’s unusual to get trench-view insights from founders who have… Continue Reading

Follow us on Twitter